SIGY 0.22 Stock Price Sigyn Therapeutics, Inc.
Range: | 0.15-7.96 | Vol Avg: | 10 | Last Div: | 0 | Changes: | 0.65 |
Beta: | -1.03 | Cap: | 0.01B | Currency: | USD | Exchange: | PNK |
Sector: | Healthcare | IPO: | Fri Jan 08 2021 | Empoloyees: | 5 |
CUSIP: | 82674U106 | CIK: | 0001642159 | ISIN: | US82674U1060 | Country: | US |
CEO: | Mr. James A. Joyce Ph.D. | Website: | https://www.sigyntherapeutics.com |
Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. It offers Sigyn Therapy, a blood purification technology to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. The company is headquartered in San Diego, California.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.